Piper Sandler Maintained a Buy Rating on Globus Medical (GMED), Kept the PT Unchanged

Globus Medical, Inc. (NYSE:GMED) is one of the Best 52-Week Low Stocks to Buy According to Analysts. On July 3, Piper Sandler analyst Matthew O’Brien maintained a Buy rating on Globus Medical, Inc. (NYSE:GMED) with a price target of $80.

The firm maintained a bullish sentiment despite the company posting a weak fiscal first quarter of 2025. Globus Medical, Inc. (NYSE:GMED) posted a revenue of $598.12, slightly down by 1.41% year-over-year, and below consensus by $27.78 million. The EPS of $0.68 also missed the target by -$0.06.

On the bright side, the US sales were steady, rising by 0.2%. Management noted that the main reason for weaker sales was fewer enabling technology deals and some supply chain issues. The timing of orders from international distributors also played a part. Despite these challenges, the company’s US spine business remained strong and offset some of the decline. Management has reaffirmed the full-year guidance and is expecting revenue between $2.8 billion and $2.9 billion.

Globus Medical, Inc. (NYSE:GMED) is a medical device company specializing in developing and commercializing solutions for musculoskeletal disorders.

While we acknowledge the potential of GMED as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.